Assessment of myocardial fibrosis in patients with systemic sclerosis using [⁶⁸Ga]Ga-FAPI-04-PET-CT.

ABSTRACT:

Purpose

Myocardial fibrosis (MF) is a factor of poor prognosis in systemic sclerosis (SSc). Direct in-vivo visualization of fibroblast activation as early readout of MF has not been feasible to date. Here, we characterize ⁶⁸Gallium-labeled-Fibroblast-Activation-Inhibitor-04 ([⁶⁸Ga]Ga-FAPI-04)-PET-CT as a diagnostic tool in SSc-related MF.

Methods

In this proof-of-concept trial, six SSc patients with and eight without MF of the EUSTAR cohort Erlangen underwent [⁶⁸Ga]Ga-FAPI-04-PET-CT and cardiac MRI (cMRI) and clinical and serologic investigations just before baseline and during follow-up between January 2020 and December 2020. Myocardial biopsy was performed as clinically indicated.

Results

[⁶⁸Ga]Ga-FAPI-04 tracer uptake was

SUBMITTER: Treutlein C 

PROVIDER: S-EPMC10119041 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature